Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05877716 · ClinicalTrials.gov registry record · NA

EPI-MINN: Targeting Cognition and Motivation - National

A NA study of Schizophrenia and Schizoaffective Disorder, sponsored by University of Minnesota.

Active
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT05877716: Active NA study of Schizophrenia and Schizoaffective Disorder, sponsored by University of Minnesota.

NCT05877716 is a NA study of Schizophrenia and Schizoaffective Disorder that is active but no longer recruiting, run by University of Minnesota. The registered enrollment target is 200 participants, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05877716, a NA study of Schizophrenia and Schizoaffective Disorder, is active but no longer recruiting, sponsored by University of Minnesota.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using a 12-week mobile intervention program. We will recruit participants who are receiving care for early psychosis from clinics across the United States. We will compare outcomes from participants who receive treatment at coordinated specialty care (CSC) early psychosis clinics to those that receive standard community care. A qualifying CSC program will provide comprehensive clinical services such as psychotherapy, medication management, psychoeducation, and work or education support. This study will be conducted remotely, and participants can participate at home with their own electronic devices. The aim of this study is to investigate a well-defined 12-week mobile intervention program specifically designed to target cognitive functioning and motivated behavior for individuals with early psychosis. Participants will complete a screening interview which will include diagnosis and symptom ratings, neurocognitive assessment, and self-reports of symptoms, behavior, and functioning. Then participants will be randomized to receive the 12-week mobile intervention, or an active control of treatment as usual. The investigators will test for differences in the clinical trajectories after training, and at two follow up appointments at 6 and 12 months post-training.

Primary Outcome

Test My Brain is reported as the total score on 4 cognitive domains. The Digit Symbol Matching ranges from 0 -300+, the Verbal Paired Associated ranges from 0 - 25, the Matrix Reasoning ranges from 0 - 35, and the Multiracial Face Emotion Identification Test ranges from 0 - 48. Test My Brain will be assessed at baseline, during pre-training, at 6 months, 12 months, and 18 months. Higher scores indicate higher cognitive function. Performance score is calculated based on accuracy and reaction spee

Conditions Studied

Schizophrenia Schizoaffective Disorder Psychosis Schizophreniform Disorders Prodromal Schizophrenia Psychosis Nos/Other Schizophrenia Spectrum and Other Psychotic Disorders Major Depression With Psychotic Features Unspecified Psychosis

Interventions

  • DEVICE Cognitive and Social Cognitive Training
  • BEHAVIORAL Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App
  • OTHER Early Psychosis Coordinated Specialty Care

Study Locations (1)

Minnesota

  • University of Minnesota Department of Psychiatry & Behavioral Sciences - Minneapolis

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2023-05-30
Est. Completion 2026-06-30
Phase NA
University of Minnesota

966 total trials

What the registry record for NCT05877716 still lists

NCT05877716 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target.

The record links to 9 conditions, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Cognitive and Social Cognitive Training is the first listed.

NCT05877716 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT05877716 about?

NCT05877716 is a clinical study titled "EPI-MINN: Targeting Cognition and Motivation - National". The purpose of this study is to perform a practice-based research project designed to assess whether cognition and motivated behavior in early psychosis can be addressed as key treatment goals within real-world settings by using a 12-week mobile intervention program. We will recruit participants who...

What is the current status of trial NCT05877716?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2023-05-30. Estimated completion is 2026-06-30.

What conditions does trial NCT05877716 study?

This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder, Psychosis, Schizophreniform Disorders, Prodromal Schizophrenia.

What interventions are being tested in trial NCT05877716?

The interventions under investigation include: Cognitive and Social Cognitive Training (DEVICE), Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App (BEHAVIORAL), Early Psychosis Coordinated Specialty Care (OTHER).

Who is sponsoring clinical trial NCT05877716?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05877716 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05877716's enrollment target sits among peer trials

200 85th of 315 higher than 228 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05877716, the US trial registry maintained by the National Library of Medicine. NCT05877716 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.